AI-generated from publicly available materials.Lords Mark Industries Limited is poised to launch its AI-driven breast cancer screening technology by April 2027, following the approval for final clinical trials across the USA, Great Britain, and Europe.
The company has successfully completed initial trials in India, which showcased the technology's capability to accurately identify breast cancer cases. As part of the next phase, which begins in January 2027, Lords Mark aims to achieve a remarkable 98% accuracy in detecting cancer at the cellular level. This innovative device is designed to be painless, portable, and radiation-free, utilizing advanced thermal sensors and AI for temperature mapping to detect abnormalities effectively.
With the global breast cancer diagnostics market projected to grow from $5.9 billion in 2025 to $11.4 billion by 2033, Lords Mark is strategically navigating regulatory pathways in India, Europe, and the US. The company is currently seeking necessary approvals and has engaged with authorities to include its technology in national screening programs, potentially enhancing affordability and access for patients.
This venture, developed in collaboration with the Centre for Materials for Electronic Technology (C-MET), represents a significant step toward commercializing homegrown healthcare solutions. The upcoming regulatory milestones will be crucial in determining the timeline for market entry, especially considering the stringent requirements set by the FDA for AI-driven medical devices. As the technology gains traction, it will be interesting to observe the competitive landscape, particularly how established imaging firms respond to the emergence of radiation-free alternatives.